|
This mdr related to the puerto rico manufacturing site has been assigned a medwatch number from the medtronic minimed northridge site, per variance 5.Currently it is unknown whether or not the device may have caused or contributed to the event as no product has been returned.The device will be returned for analysis and further information will follow once the analysis has been completed.No conclusion can be drawn at this time.Medtronic submits this report to comply with fda regulations 21 cfr parts 4 and 803.Medtronic has made reasonable efforts to provide as much relevant information as is available to the company as of the submission date of this report.This report does not constitute an admission or a conclusion by fda, medtronic, or its employees that the device, medtronic, or its employees caused or contributed to the event described in the report.Any required fields that are unpopulated are blank because the information is currently unknown or unavailable.Medtronic will submit a supplemental report if additional relevant information becomes known.
|
|
It was reported to medtronic minimed that the customer experienced hyperglycemia.The customer also reported insulin flow block alarm and blank display.Blood glucose value at the time of event was 400 mg/dl.The customer was treated with manual injection.The event involved product(s) mmt-1884l, mmt-332a, mmt-242a.Troubleshooting was partially performed.Customer using the correct battery cap for the pump.The pump did not show any signs of damage.It is unknown whether the customer was using the auto mode/smart guard feature at the time of the event.It is unknown whether the customer was using the insulin pump system within 48 hours of reported event.No further patient complications were reported.The customer will discontinue use of the insulin pump.Mmt-1884l was requested and the customer response was that the device will be returned.No product return is required for mmt-332a.No product return is required for mmt-242a.
|